BTIG raised the firm’s price target on Guardant Health (GH) to $145 from $140 and keeps a Buy rating on the shares. The company delivered another upbeat earnings call and continues to post strong numbers, the analyst tells investors in a research note. Guardant is the premier liquid biopsy company in the diagnostics industry and the firm believes this is a “must own” market leader in the space, BTIG adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $130 from $120 at Stifel
- Guardant Health price target raised to $135 from $125 at Canaccord
- Guardant Health price target raised to $150 from $135 at Citi
- Guardant Health price target raised to $130 from $120 at Barclays
- Guardant Health reports Q4 EPS (50c), consensus (47c)